ACM
HZNP

Abrams Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Abrams Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-890,993
Closed -$91.6M – 17
2023
Q2 		$91.6M Buy
+890,993
New +$94M 2.64% 12

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Abrams Capital Management's HZNP Position: Q3 2023 in Review

Abrams Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 890,993 shares — an estimated $91.6M sold.

Abrams Capital Management first reported a position in HZNP in Q2 2023 and held it in 1 quarter. The position peaked at $91.6M in Q2 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Abrams Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Abrams Capital Management sold 890,993 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $91.6M.
  • Abrams Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2023 and held it in 1 quarter.
  • Abrams Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $91.6M in Q2 2023.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Abrams Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.